Timo Ilmari Vaara

Northern Antibiotics Oy engages in the discovery and development of novel antibiotics against multidrug-resistant gram-negative bacteria. It develops compounds, which are active against difficult-to-treat gram-negative bacteria, such as multi-resistant Escherichia coli, Klebsiella pneumoniae, other species of Enterobacteriaceae, and Acinetobacter baumannii. The company was founded by Martti Sakari Vaara and Timo Ilmari Vaara in 2003 and is headquartered in Helsinki, Finland.

Northern Antibiotics Oy engages in the discovery and development of novel antibiotics against multidrug-resistant gram-negative bacteria. It develops compounds, which are active against difficult-to-treat gram-negative bacteria, such as multi-resistant Escherichia coli, Klebsiella pneumoniae, other species of Enterobacteriaceae, and Acinetobacter baumannii. The company was founded by Martti Sakari Vaara and Timo Ilmari Vaara in 2003 and is headquartered in Helsinki, Finland.

Northern Antibiotics Oy engages in the discovery and development of novel antibiotics against multidrug-resistant gram-negative bacteria. It develops compounds, which are active against difficult-to-treat gram-negative bacteria, such as multi-resistant Escherichia coli, Klebsiella pneumoniae, other species of Enterobacteriaceae, and Acinetobacter baumannii. The company was founded by Martti Sakari Vaara and Timo Ilmari Vaara in 2003 and is headquartered in Helsinki, Finland.